ViGenCell Inc. (KOSDAQ:308080)

Market Cap	229.59B +314.6%
Revenue (ttm)	278.95M
Net Income	-12.56B
EPS	-650.72
Shares Out	20.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,997,173
Average Volume	1,326,820
Open	9,600.00
Previous Close	7,390.00
Day's Range	7,750.00 - 9,600.00
52-Week Range	2,760.00 - 17,360.00
Beta	0.84
RSI	84.50
Earnings Date	n/a

About ViGenCell

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, Sou...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 64
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308080